Lyell Immunopharma Stock (NASDAQ:LYEL)
Previous Close
$1.11
52W Range
$0.85 - $3.26
50D Avg
$1.21
200D Avg
$1.84
Market Cap
$287.60M
Avg Vol (3M)
$1.12M
Beta
-0.48
Div Yield
-
LYEL Company Profile
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Performance
Peer Comparison
Ticker | Company |
---|---|
SANA | Sana Biotechnology, Inc. |
NUVB | Nuvation Bio Inc. |
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
MRUS | Merus N.V. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
INBX | Inhibrx Biosciences, Inc. |
GBIO | Generation Bio Co. |
KRON | Kronos Bio, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
NKTX | Nkarta, Inc. |
STTK | Shattuck Labs, Inc. |